摘要
目的评价使用美罗培南治疗医院获得性肺炎（HAP）的安全性和有效性。方法使用前瞻性、开放性、非比较的方法研究美罗培南治疗医院获得性肺炎的安全性和有效性，在进入研究前，通过支气管肺泡灌洗或者血液培养进行病因学调查；入选病例使用美罗培南1g／8h静脉内给药，大部分患者的治疗时间是3～7d。结果35例（66．04％）患者治愈或好转，6例（11．32％）死亡，有11例（21％）出现临床并发症，但同美罗培南无明显关系。结论美罗培南是有效、耐受性良好的药物，本研究中死亡率较低同诊断后首先使用美罗培南控制感染有关。
OBJECTIVE To evaluate the efficacy and safety of meropenem as first choice for hospital acquired pneumonia （HAP） treatment in intensive care units （ICU） in Southwest Hospital. METHODS The usage of meropenem for the patients with HAP in ICU was studied by a prospective, open, and non-comparative trial. Prior to the clinical trial, the preliminary experiment on etiologic investigation was done through bronchoalveolar lavage and blood cultures. In the trial, all patients were treated intravenously with meropenem at a dose of lg every 8 hours and 3 to 7 days were established as a treatment duration period. RESULTS After the meropenem therapy, 35 patients （66%） showed either cure or improvement. Mortality was 11% at the end of therapy. Clinical complications were observed in 11 patients （21%）, with none of them definitely related to the study drug. CONCLUSIONS Meropenem is effective and well-tolerated as monotherapy for most HAP patients in our ICU. The low mortality rate in this study might have been attributed to the first choice use of this drug.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2006年第8期930-932,共3页
Chinese Journal of Nosocomiology
关键词
美罗培南
医院获得性肺炎
治疗
Meropenem
Hospital acquired pneumonia
Treatment
